NitroMed/NAACP alliance
Executive Summary
NitroMed provides a $1.5 mil. grant to the National Association for the Advancement of Colored People to develop "health advocacy initiatives towards equal access to quality healthcare," the firm announces Dec. 14. Among other initiatives, the grant will support the development of a "consensus paper on the state of African American healthcare and the impact of Medicare" and an Advocacy Action Plan for the NAACP National Health Leadership Committee. NitroMed markets BiDil (isosorbide dinitrate/hydralazine), which was approved in June for treatment of heart failure in self-identified black patients, and is the first therapy indicated for a specific ethnic population (1"The Pink Sheet" June 27, 2005, p. 5)...
You may also be interested in...
BiDil Approval In Blacks Is Step Toward Personalized Medicine, FDA Says
The approval of NitroMed's BiDil for treatment of heart failure in self-identified blacks is a step in the direction of drugs based on patient characteristics
Signs Of Hope But Obstacles Remain For Swiss Device MRA With EU
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.
Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: